Related Experiment Video
Updated: Jun 19, 2025
05:05
Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
10.7K
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study
Mara Caroprese1, Manuel Conson1, Angela Barillaro1
1Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
Anticancer Research
|July 26, 2024
Summary
Neoadjuvant systemic therapy (NAT) for breast cancer shows comparable overall survival and distant metastasis-free survival to adjuvant therapy (AD). Pathological node response is a key predictor of outcomes in NAT patients, enabling personalized treatment.
Area of Science:
- Oncology
- Breast Cancer Research
- Clinical Therapeutics
Background:
- Neoadjuvant systemic therapy (NAT) aims to improve surgical outcomes and prevent distant relapse in breast cancer.
- NAT offers potential for personalized treatment by allowing therapy adjustment based on treatment response.
- Evidence supporting improved outcomes with NAT compared to adjuvant therapy (AD) is still developing.
Purpose of the Study:
- To evaluate the effectiveness of NAT compared to AD in breast cancer patients.
- To assess overall survival (OS), loco-regional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS).
- To identify prognostic factors influencing outcomes in patients treated with NAT.
Main Methods:
- Retrospective analysis of 127 breast cancer patients treated with NAT and postoperative radiotherapy (2004-2021).
- Comparison with a matched patient cohort treated with AD during the same period.
- Outcomes analyzed included OS, LRRFS, and DMFS.
Main Results:
- Five-year predicted OS: 87% (NAT) vs. 81.5% (AD) (p=0.179).
- Five-year predicted LRRFS: 93.2% (NAT) vs. 100% (AD) (p=0.005).
- Five-year predicted DMFS: 84.6% (NAT) vs. 82.1% (AD) (p=0.367).
- In NAT group, pathological node response was a significant prognostic factor for OS (95.6% vs. 75.1%).
Conclusions:
- NAT demonstrates comparable efficacy to AD in terms of DMFS and OS.
- NAT provides a valuable opportunity for personalized treatment modulation, particularly in node-positive breast cancer.
- Pathological node response is a critical indicator for predicting outcomes in NAT patients.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
01:20Comparing the Survival Analysis of Two or More Groups
168
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
168
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K